- Home
- CTRN vs ENGN Comparison
CTRN vs ENGN Comparison
Compare CTRN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- ENGN
- Stock Information
- Founded
- CTRN 1946
- ENGN 1999
- Country
- CTRN United States
- ENGN Canada
- Employees
- CTRN N/A
- ENGN N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- ENGN
- Sector
- CTRN Consumer Discretionary
- ENGN
- Exchange
- CTRN Nasdaq
- ENGN Nasdaq
- Market Cap
- CTRN 281.4M
- ENGN 321.5M
- IPO Year
- CTRN 2005
- ENGN N/A
- Fundamental
- Price
- CTRN $32.94
- ENGN $6.07
- Analyst Decision
- CTRN Buy
- ENGN Buy
- Analyst Count
- CTRN 2
- ENGN 8
- Target Price
- CTRN $31.50
- ENGN $21.50
- AVG Volume (30 Days)
- CTRN 110.8K
- ENGN 222.4K
- Earning Date
- CTRN 08-26-2025
- ENGN 09-11-2025
- Dividend Yield
- CTRN N/A
- ENGN N/A
- EPS Growth
- CTRN N/A
- ENGN N/A
- EPS
- CTRN N/A
- ENGN N/A
- Revenue
- CTRN $782,716,000.00
- ENGN N/A
- Revenue This Year
- CTRN $6.80
- ENGN N/A
- Revenue Next Year
- CTRN $4.61
- ENGN N/A
- P/E Ratio
- CTRN N/A
- ENGN N/A
- Revenue Growth
- CTRN 3.32
- ENGN N/A
- 52 Week Low
- CTRN $16.18
- ENGN $2.65
- 52 Week High
- CTRN $39.37
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- CTRN 45.29
- ENGN 56.13
- Support Level
- CTRN $33.06
- ENGN N/A
- Resistance Level
- CTRN $34.74
- ENGN $6.54
- Average True Range (ATR)
- CTRN 1.95
- ENGN 0.50
- MACD
- CTRN -0.47
- ENGN -0.12
- Stochastic Oscillator
- CTRN 2.58
- ENGN 92.74
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.